comparemela.com
Home
Live Updates
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study : comparemela.com
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
VANCOUVER, British Columbia, Oct. 24, 2022 -- Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that it has entered an... | October 24, 2022
Related Keywords
Miami ,
Florida ,
United States ,
Canada ,
United Kingdom ,
Yale School ,
Vancouver ,
British Columbia ,
British ,
Canadian ,
Christopherj Moreau ,
Deepak Cyril Dsouza ,
Deepak Dsouza ,
No Securities Exchange ,
Yale University ,
Yale School Of Medicine ,
Algernon Pharmaceuticals ,
Algernon Pharmaceuticals Inc ,
Neither The Canadian Securities Exchange ,
Yale University School Of Medicine ,
Company Or Algernon ,
Canadian Securities Exchange ,
Schizophrenia Neuropharmacology Research Group ,
Globenewswire Inc ,
Investigator Initiated Clinical Trial Agreement ,
Professor Deepak Cyrild Souza ,
United States Government ,
Deepakd Souza ,
Neuropharmacology Research Group ,
University School ,
Market Regulator ,
Algernon Pharmaceuticals Inc Stock Exchange ,
News ,
Information ,
Press Release ,
022 ,
Algernon ,
Pharmaceuticals ,
Linical ,
Stage ,
Harmaceutical ,
Development ,
Company ,
Us ,
Pleased ,
O ,
Nnounce ,
Hat ,
It ,
Gas ,
Ntered Agn Ca01559r4008 ,
comparemela.com © 2020. All Rights Reserved.